To report clinical outcomes of 125 I low-dose-rate prostate brachytherapy (LDR-PB) as monotherapy or combined with androgen-deprivation therapy (ADT) and/or external beam radiotherapy (EBRT) in high-risk localised prostate cancer.
Introduction
Low-dose-rate prostate brachytherapy (LDR-PB) using 125 Iseed implants is a standard therapeutic approach for low-risk localised prostate cancer and selected intermediate-risk patients [1, 2] . Combined therapy, in the form of an LDR-PB boost to external beam radiotherapy (EBRT) with or without androgen-deprivation therapy (ADT), has been recommended as an option for the treatment of patients with prostate cancer with a high risk of disease relapse [1] [2] [3] . These recommendations, based on large cohort series, are now supported by Level 1 Evidence from the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) randomised controlled trial [4] .
In the ASCENDE-RT trial, National Comprehensive Cancer Network (NCCN) criteria were used to identify men with high-and intermediate-risk disease. With a median follow-up of 6.5 years the trial showed superior relapse-free survival (RFS) after an 125 use of 103 Pd seeds [5] [6] [7] . The treatment protocol for high-risk disease with the tri-modal approach, ADT, EBRT and 125 Iseed implant boost, described in the ASCENDE-RT trial, is similar to that used in our institution. Herewith we report on clinical outcomes and toxicity profiles of high-risk patients who have been treated in the LDR-PB programme at the Royal Surrey NHS Trust since 1999.
Patients and Methods

Patient Selection and Stratification
Our prospectively maintained database was accessed on 14 June 2017. From 3596 patients enrolled up to that date, we selected for patients with >3 years post-implant, a minimum of four PSA measurements (the pre-treatment initial PSA (iPSA) and three post-implantation values), documented pretreatment clinical staging, and Gleason score. These selection steps resulted in 2182 consecutive patients available for analyses, of whom 267 (12.2%) were identified as high-risk by the National Institute for Health and Care Excellence (NICE) guideline criteria [8] and 202 (9.3%) by the NCCN criteria [9] (Fig. 1) . The selection steps did not significantly alter the proportions of high-risk patients; of 3596 patients enrolled, 3506 were risk-classifiable and of these 457 (13.0%) were high-risk by NICE criteria (P = 0.5) and 359 (10.2%) by NCCN criteria (P = 0.3).
Biochemical failure was defined by a PSA value nadir plus 2 ng/mL (nadir +2) without a return to levels below the nadir +2 level (i.e. not a bounce). Treatment failure was defined as a biochemical failure and/or documented clinical failure. Metastatic status was confirmed by a review of clinical notes of patients with treatment failure.
Therapy
Our brachytherapy technique has been described elsewhere [10, 11] . The prescription dose for 125 I monotherapy was 145 and 110 Gy as a boost to EBRT. A two-stage technique was used up to 2007 after which the 4D Brachytherapy real-time technique was adopted [10, 11] .
For patients who received adjuvant EBRT combined with brachytherapy the prescription dose was 45 Gy in 25 fractions delivered to the pelvis by 3D-conformal EBRT. In 2007, the prescription dose changed to 44 Gy in 22 fractions delivered to the prostate and seminal vesicles. Patients with the highest risk (e.g. Gleason >7, T3) received pelvic nodal irradiation to 50.4 Gy in 28 fractions. Patients who received triple therapy (ADT+EBRT+LDR-PB) had 3 months neoadjuvant hormone therapy, which was continued for a further 3 months after implantation. The ideal regimen and duration of ADT combined with brachytherapy has still to be determined, therefore clinicians used the best available evidence at the time. Less than 22% of patients received neoadjuvant ADT for >1 year and no patient received ADT for >3 years.
Patients were prescribed tamsulosin 400 mg daily for the first 3-6 months after implantation. They were encouraged to take a phosphodiesterase type 5 inhibitor if erectile function was sub-optimal and as a preventative approach [12] once or twice per week to maintain nocturnal and early morning erections.
Dosimetry
A post-implantation CT was conducted in all patients for post-implantation dosimetry and quality assurance. Postimplantation dosimetry values were not significantly different between treatment types (not shown).
Toxicity Outcomes
As previously described [13] , urinary and bowel toxicity scores were obtained using the international prostate symptom score (IPSS) questionnaire (including the urinary quality-of-life [QoL] domain) and the bowel function subscale of the European Organisation for Research and Treatment of Cancer (EORTC) prostate-specific QLQ-PR25 questionnaire. The International Index of Erectile Function (five-item version, IIEF-5) questionnaire was used for assessment of erectile function. Patients with complete scores documented at baseline and follow-up visits were included in the analysis. The number of patients for each QoL assessment is shown in Table S1 . Physician-reported toxicity was assessed by the 
N=2182
High-risk (NICE-CG175)
High-risk (NCCN-2017v2)* iPSA>20 ng/mL or Gleason score >7 or ≥ T2c N=267
iPSA >20 ng/mL or Gleason score >7 or T3 N=202 Common Terminology Criteria for Adverse Events grading system (CTCAE) version 3 [14] .
Statistical Analysis
Statistical analyses were performed within R statistical environment (R Foundation for Statistical Computing, Vienna, Austria) [15] . The 'survival' package was used for Kaplan-Meier estimates of RFS, overall survival (OS), prostate cancer-specific survival (PCSS), metastasis-free survival (MFS), log-rank tests and Coxph regression (proportional hazards confirmed with the coxzph test). Survival objects were right censored using the data download date. Categorical data (proportions) were analysed using Fisher's exact test. Unpaired two-tailed t-tests were used for continuous data.
Results
We identified 267 and 202 high-risk patients using the NICE and NCCN criteria, respectively ( Fig. 1 ). High-risk patients defined by NICE criteria had lower iPSA levels, a greater proportion of patients with a Gleason score <7, and a greater proportion of patients treated with LDR-PB monotherapy relative to the NCCN-defined group (Table 1) . The NICEdefined group also showed that all LDR-PB monotherapy patients had a single high-risk factor, where 59 (90%) were defined as high-risk by a clinical stage T2c, three (5%) by an iPSA >20 ng/mL, two (3%) by a Gleason >7, and two (3%) by a clinical stage T3 (Fig. S1 ). Conversely, 57 ADT+LDR-PB patients (97%) had a single high-risk factor, where 45 (76%) were high-risk defined by a stage T2c, 11 (19%) by a Gleason >7, and one (2%) by an iPSA >20 ng/mL. Two (3%) ADT+LDR-PB patients had more than one high-risk factor, one a T2c with Gleason >7 and one T3 with Gleason >7 (Fig. S1 ). For triple therapy (ADT+EBRT+LDR-PB) patients, 114 (80%) had a single high-risk factor, where 46 (32%) were defined as high-risk by a T2c clinical stage, 19 (13%) by a T3 stage, 23 by an iPSA >20 ng/mL, and 26 by a Gleason >7. In all, 27 (19%) patients had two high-risk factors; 20 with a Gleason >7 (of whom nine a T2c and 11 a T3 clinical stage) and seven with an iPSA >20 ng/mL (of whom four and three patients were T2c and T3 clinical stage, respectively). One patient had three high-risk factors (T2c, Gleason >7 and iPSA >20 ng/mL; Fig. S1 ).
Kaplan-Meier analyses showed 7-and 9-year postimplantation RFS estimates of 91% and 89% in the NICEdefined group, respectively, and 90% and 87% in the NCCN-defined group, respectively (log-rank P = 0.637; Fig. 2 -left panel). These estimates included 43 (16%) and 35 (17%) NICE-and NCCN-defined patients, respectively, with a PSA follow-up time <3 years, of whom 10 (4%) and nine (4%) NICE-and NCCN-defined patients, respectively, had treatment failure within the first 3 years after implantation.
RFS estimates were similar between treatment types (Fig. 2 mid and right panels, and Table 2 ) and after adjustment for age at therapy, iPSA, Gleason score, clinical stage, and dose received (multivariable Cox proportional hazards regression, Table S2 ). The proportions of patients with controlled disease (relapse-free) were similar between the three treatment regimens, as were the proportions of patients with metastasis, patients alive with or without disease, prostate cancer-specific or non-specific deaths ( Table 2 ). All death events unrelated to prostate cancer had no evidence of disease progression. OS of all high-risk NICE-defined patients showed 94% and 93% survival at 7 and 9 years after implantation, respectively, and in the high-risk NCCN-defined patients, 94% and 94% survival, respectively (log-rank P = 0.481, not shown). OS estimates were similar between treatment types (Table 2) , as were PCSS and MFS.
Health-related QoL assessments are shown in Fig. 3 . The IPSS and urinary domain scores showed that the acute rise soon after treatment with gradual return to baseline was not different between treatment types. Scores for bowel symptoms were not significantly different between treatments nor were the proportion of patients with preserved potency (defined by an IIEF-5 score >11 at base and post-implantation follow-up).
There were 34 Grade 2 and one Grade 3 adverse events by CTCAE version 3.0 criteria in 27 (10%) patients (not shown). Of Grade 2 events, there were 10 urinary stricture/stenosis, eight GU haemorrhages, five rectal haemorrhages, three urinary incontinence, two cystitis, two dysuria, two severe perineal pain, one proctitis, and one GU obstruction. The single Grade 3 event was a urinary stricture/stenosis. Of the 35 adverse events, 22 occurred after triple therapy, of these nine were urinary stricture/stenosis, six GU haemorrhages, three rectal haemorrhages, one cystitis, one dysuria, one proctitis, and one urinary incontinence. The single Grade 3 event of urinary stricture/stenosis occurred in a patient who received ADT+LDR-PB. The incidence of all GU events was 7.2% for LDR-PB (with or without ADT) and 12.7% for triple therapy (Fisher's P = 0.2). The incidence of urinary stricture/ stenosis, the most common adverse event, was 1.6% for LDR-PB (with or without ADT) and 6.3% for triple therapy (Fisher's P = 0.07).
Discussion
Our present results compare favourably with respect to ASCENDE-RT, where the primary endpoint was biochemical progression-free survival with failure events identified by a PSA value over a nadir +2 ng/mL threshold. The 7-and 9-year Kaplan-Meier biochemical progression-free survival estimates were 83% and 78%, respectively for high-risk patients defined by NCCN criteria [16] . In our present cohort of high-risk patients the 7-and 9-year Kaplan-Meier RFS estimates were 90% and 89%, respectively in patients who
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© 2018 The Authors BJU International © 2018 BJU International received combined ADT+EBRT+LDR-PB whether defined as high-risk by NICE or by NCCN criteria (Table 2) .
We found no difference in any of the survival estimates between treatment types. Monotherapy used in 66 (25%) patients performed equally efficiently to double-or tripletherapy patients (Fig. 2) A comparison of GU and gastrointestinal morbidity between ASCENDE-RT and our present study is limited by differences in morbidity scoring systems. The ASCENDE-RT trial used a modified Late Effects Normal Tissue Task Force -Subjective, Objective, Management, Analytic (LENT-SOMA) scale to report adverse events [17] , whereas we used the CTCAEversion 3 score. ASCENDE-RT reported a significant increase in acute Grade 2 GU morbidity in the LDR PB boost arm (30% Grade 2 crude incidence vs 16% in the dose-escalated EBRT arm). We saw no statistically significant difference in the incidence of GU adverse events between LDR-PB, with or without ADT, and triple therapy (7.2% vs 12.7%, respectively). GU toxicity has been linked to a high brachytherapy radiation dose delivered to the membranous urethra in the GU diaphragm region [18] . Our favourable GU toxicity results may therefore be explained by a reduced dose to the membranous urethra as delivered by the 4D-Brachytherapy technique [19] , which utilises both stranded and loose seeds, as well as real-time intraoperative dose planning.
Results from radiation and surgical approaches to treatment of patients with high-risk prostate cancer are difficult to compare in the absence of prospective randomised trials, differences in risk stratification criteria, and definition of biochemical failure. Additionally, patients treated with EBRT or LDR-PB are often older, have more comorbidities and worse prognostic features. Results from the Prostate Cancer Study Group published in 2012 [20] compared outcomes from studies involving high-risk patients treated with surgery (N = 5149), EBRT (N = 3828), and brachytherapy (with or Table 2 for breakdown of estimates by treatment type.
© 2018 The Authors BJU International © 2018 BJU International 613 (86) 123 (87) 23 (88) 33 (85) 119 (87) Relapse 7 (11) 8 (14) 19 (13) 3 (12) 6 (15) 18 (13) Metastasis 1 (2) 5 (8) 10 (7) 1 (4) 5 (13) 10 (7) Alive 61 (92) 54 (92) 132 (93) 25 (96) 37 (95) 130 (95) Deceased 5 (8) 5 (8) 10 (7) 1 (4) 2 (5) 7 (5) AWOD 60 (91) 50 (85) 127 (89) 24 (92) 33 (85) 124 (91) AWD 1 (2) 4 (7) 5 (4) 1 (4) 4 (10) 6 (4) DPCa 1 (2) 3 (5) 6 (4) 0 (0) 2 (5) 5 (4) DNPCa.NEP without ADT and/or EBRT, N = 4390). For high-risk patients, PSA relapse-free progression was superior after EBRT combined with brachytherapy relative to brachytherapy alone, surgery alone, or EBRT alone. However, Ciezki et al. [21] recently reported in a large non-randomised study of 2557 high-risk patients defined by NCCN criteria that LDR-PB 125 I-seed implantation can be superior to EBRT or radical prostatectomy for disease control of high-risk prostate cancer with reduced toxicity.
A recent review of surgical series [3] reported biochemical RFS rates ranging from 27% to 55% at 10 years after treatment (defined with a 0.2 ng/mL cut-off). Our present results show 89.2% RFS 10 years after implantation by the Phoenix (nadir +2) definition and that 92% of relapse-free patients with an available PSA 10 years after implantation had a PSA level of ≤0.2 ng/mL (Fig. S2) .
The high-risk prostate cancer population is heterogeneous. Our present data indicate that monotherapy is an option for high-risk patients with low iPSA and Gleason scores, where RFS estimates were similar to patients who underwent triple therapy.
Our present prospective study is unable to determine the extent to which brachytherapy contributed to outcomes in the triple therapy patients. However, ASCENDE-RT now clearly shows that clinical outcome is dependent upon the addition of an LDR-PB component to the radiation delivery.
In conclusion, LDR-PB should be offered to patients with high-risk prostate cancer. The choice between monotherapy and combined treatment should be discussed with the patient taking into account comorbidities and presence of multiple intermediate-or high-risk factors. The NICE criteria identify greater numbers of 'favourable' high-risk disease patients and, as shown by the long-term clinical outcomes we report here, the NICE criteria can be used to determine suitable treatment options where patients could benefit from LDR-PB as monotherapy or in combined treatment. 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Risk stratification criteria breakdown of NICEdefined high-risk patients. (A) Jitter plot for pretreatment initial PSA (iPSA) levels, Gleason score and clinical stage (cStage) of NICE-defined high-risk patients treated with lowdose-rate prostate brachytherapy (LDR-PB) monotherapy, androgen-deprivation therapy (ADT) and brachytherapy (ADT+LDR-PB) or ADT and external beam radiotherapy (EBRT) with a brachytherapy boost (ADT+EBRT+LDR-PB).
B. Summary table of number of high-risk factors by treatment modality. Figure S2 . 10-year RFS and 0.2 ng/mL PSA cut-off in NICEdefined relapse-free patients. A. Kaplan-Meier RFS estimates at 5 and 10 years after implantation. Dashed lines represent the 95% CI. B. Bar plot for the proportion of patients with a PSA ≤0.2 ng/mL at ≥5 years after implantation. Table S1 . Number of high-risk NICE patients with complete values at baseline and follow-up time points by treatment type. Table S2 . Relapse-free survival (RFS) Cox proportional hazards regression.
